Acute pharmacodynamic responses to exenatide:

Drug-induced increases in insulin secretion and glucose effectiveness

Simeon I. Taylor MD, PhD[1] | May E. Montasser PhD[1] | Ashley H. Yuen MD[1] |

Hubert Fan[2] | Zhinoosossadat Shahidzadeh Yazdi MD[1] | Hilary B. Whitlatch MD[1] |

Braxton D. Mitchell PhD, MPH[1] | Alan R. Shuldiner MD[1] | Ranganath Muniyappa MD PhD[2] |

Elizabeth A. Streeten MD[1] | Amber L. Beitelshees PharmD, MPH[1]

[1] Department of Medicine, Division of Endocrinology, Diabetes, and Nutrition, University of

Maryland School of Medicine, Baltimore, MD 21201, USA

[2] Diabetes, Endocrinology, and Obesity Branch, National institute of Diabetes and Digestive and

Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA

Correspondence

Simeon I. Taylor, MD, PhD, Department of Medicine, University of Maryland School of Medicine,

Baltimore, MD 21201, USA

Email: staylor2@som.umaryland.edu

Funding information: American Diabetes Association (1-16-ICTS-112) and National Institute of

Diabetes and Digestive and Kidney Disease (R01DK130238, T32DK098107, and

P30DK072488)

Trial registration: NCT05762744 (clinicaltrials.gov)

Study review and approval: Institutional Review Board of the University of Maryland Baltimore

ABSTRACT

Background: GLP1R agonists provide multiple benefits to patients with type 2 diabetes – including improved glycemic control, weight loss, and decreased risk of major adverse cardiovascular events. Because drug responses vary among individuals, we initiated investigations to identify genetic variants associated with the magnitude of drug responses.

Methods: Exenatide (5 μg, sc) or saline (0.2 mL, sc) was administered to 62 healthy volunteers. Frequently sampled intravenous glucose tolerance tests were conducted to assess the impact of exenatide on insulin secretion and insulin action. This pilot study was designed as a crossover study in which participants received exenatide and saline in random order.

Results: Exenatide increased first phase insulin secretion 1.9-fold ($p=1.9 \times 10^{-9}$) and accelerated the rate of glucose disappearance 2.4-fold ($p=2 \times 10^{-10}$). Minimal model analysis demonstrated that exenatide increased glucose effectiveness (S_g) by 32% ($p=0.0008$) but did not significantly affect insulin sensitivity (S_i). The exenatide-induced increase in insulin secretion made the largest contribution to inter-individual variation in exenatide-induced acceleration of glucose disappearance while inter-individual variation in the drug effect on S_g contributed to a lesser extent ($\beta=0.58$ or 0.27, respectively).

Conclusions: This pilot study provides validation for the value of an FSIGT (including minimal model analysis) to provide primary data for our ongoing pharmacogenomic study of pharmacodynamic effects of semaglutide (NCT05071898). Three endpoints provide quantitative assessments of GLP1R agonists' effects on glucose metabolism: first phase insulin secretion, glucose disappearance rates, and glucose effectiveness.

Registration: NCT02462421 (clinicaltrials.gov)

Funding: American Diabetes Association (1-16-ICTS-112); National Institute of Diabetes and Digestive and Kidney Disease (R01DK130238, T32DK098107, P30DK072488)

1 | Introduction

Head-to-head comparative effectiveness studies demonstrate that diabetes drugs are not strongly differentiated with respect to their effectiveness to decrease mean HbA1c [1]. Nevertheless, individual patients vary widely in their responses to individual therapies. For example, semaglutide (1.0 mg/wk) decreased HbA1c by an average of 1.64% (SEM ≈ 0.05%; SD ≈ 0.95%) in patients with baseline HbA1c=8.17% [2]. The observed magnitude of standard deviation suggests that some patients experienced little if any decrease in HbA1c while others experienced >2.5% HbA1c-lowering. This inter-individual variation may result from genetics, environment, or interplay between both factors. Pharmacogenetics has potential to guide treatment decisions, enabling clinicians to recommend optimal therapy for individual patients based on individualized predictors of responsiveness and susceptibility to adverse effects [1].

Pharmacogenomic studies have identified genetic variants associated with the magnitude of responses to several diabetes drugs, including metformin, sulfonylureas, and GLP1 receptor agonists [3-7]. While some genetic variants alter a drug's pharmacokinetics, other genetic variants alter pharmacodynamics by altering functions of proteins that mediate drug responses. Although genetic variation in pharmacokinetics may be less relevant for responses to an injectable peptide drug such as exenatide, genetic variants in the *GLP1R* gene have been reported to be associated with pharmacodynamic responses to GLP1 receptor agonists [4-7].

We initiated this clinical trial as a pilot and feasibility study for our ongoing genome-wide association study of responses to semaglutide (NCT05071898). Specifically, we conducted frequently sampled intravenous glucose tolerance tests (FSIGT) to assess pharmacodynamic responses to a rapid-acting GLP1R agonist (exenatide): glucose-stimulated insulin secretion and the rate of glucose disappearance (minutes 25-50 in an FSIGT). Herein we summarize pharmacodynamic responses to exenatide in the overall study population as well as in

participants who were homozygous for two genetic variants, *GIPR* (p.E354Q; rs1800437) and

GCGR (p.G40S; rs850763). As expected, exenatide triggered a substantial increase in glucose-

stimulated insulin secretion. Variation in the magnitude of the increase in glucose-stimulated

insulin secretion accounted for over half the inter-individual variation in the magnitude of

exenatide-triggered acceleration of glucose disappearance. Although exenatide did not trigger a

statistically significant increase in insulin sensitivity (S_i) as estimated by Bergman's minimal

model [8], acute administration of a single dose of exenatide triggered a 32% increase in glucose

effectiveness (S_g). Several mechanisms have been reported previously to contribute to effects

of GLP1R agonists on glucose metabolism [9-11]: (a) enhancement of glucose-stimulated insulin

secretion; (b) delayed gastric emptying and slowed intestinal motility; (c) weight loss; and (d)

increased glucose effectiveness [12-15].

2 | Methods

2.1 | Study population: recruitment and screening

The Old Order Amish population of Lancaster County, PA emigrated from Central Europe in the early 1700's. There are currently ~40,000 Old Order Amish individuals in the Lancaster area. University of Maryland School of Medicine researchers have been studying genetic determinants of cardiometabolic health in this population since 1993. To date, ~10,000 Amish adults participated in one or more studies as part of the Amish Complex Disease Research Program (http://www.medschool.umaryland.edu/endocrinology/Amish-Research-Program/). These studies generated a genotype database that was used to identify individuals with any of three genotypes who were eligible for our clinical trial: (a) homozygotes for a missense variant in *GIPR* (p.E354Q; rs1800437); (b) homozygotes for a missense variant in *GCGR* (p.G40S; rs850763); and (c) individuals who were homozygous for the "wild type" major alleles of *GIPR* and *GCGR*. A research nurse, accompanied by a member of the Amish community, made home visits to invite individuals to participate in the study. If they expressed interest, the study was explained in detail; potential participants were invited to sign an informed consent form. Thereafter, the research nurse obtained a medical history; measured height, weight and blood pressure; and obtained blood samples for screening laboratory tests (hematocrit, fasting plasma glucose, serum creatinine, serum AST, serum ALT, plasma TSH, and HbA1c). The study included two frequently sampled intravenous glucose tolerance tests (FSIGT).

2.2 | Study design: overview

The study was designed as a crossover study in which healthy individuals were randomized between administration of exenatide (5 μg, sc) or saline (0.2 mL, sc). Fifteen minutes after the injections, participants underwent a frequently sampled intravenous glucose tolerance test (FSIGT). A second FSIGT was conducted 5-28 days

later; each participant received the treatment (either saline or exenatide) not

administered for the first FSIGT. All procedures were reviewed and approved by the

University of Maryland Baltimore IRB.

2.3 | Frequently sampled intravenous glucose tolerance tests

After an overnight fast, participants were transported to the Amish Research Clinic where

FSIGTs were performed [8,16-18]. Two 20-gauge catheters were placed in antecubital veins

through which normal saline (60 mL/hr) was administered – one for intravenous administration

of D50W and one for obtaining blood samples. The infusion was stopped at times when blood

samples were withdrawn. To minimize dilution of blood, small amounts of blood were discarded

prior to obtaining blood samples. After placement of intravenous catheters, participants received

subcutaneous injections of either exenatide (5 µg, sc) or saline (0.2 mL, sc). Fifteen minutes

after the subcutaneous injections, an intravenous bolus of glucose (0.3 g/kg) was infused over

two minutes. Thirty-one timed blood samples were obtained between -10- and +180-minutes

relative to the i.v. glucose infusion [18]. Plasma samples were used to assay levels of glucose and

insulin.

2.4 | Power calculations

We aimed to recruit 24 research participants for each of the three genotypes. We estimated that

these recruitment targets provided 80% power (with p=0.05) to detect association with a 35%

change in first-phase insulin secretion and a 25% change in glucose disappearance rate for

homozygous variant compared to homozygous wild-type individuals. However, the clinical trial

was terminated early when it became apparent that we would not meet our recruitment targets

within the available budget.

2.5 | Eligibility criteria

To be eligible to participate in the clinical trial, individuals were required to be of Amish descent,

at least 18 years old, and have BMI between 18-40 kg/m^2. Exclusion criteria are summarized in

the Supplementary Appendix.

2.5 | Clinical chemistry

Processing of blood samples and laboratory methods are summarized in the Supplementary

Appendix.

2.6 | Data and statistical analyses

We established two primary end points: drug effects on (a) first phase insulin secretion and (b)

glucose disappearance rate. Fig. 1 presents untransformed data on plasma levels of insulin and

glucose. Tables 1 and 2 present analyses of logarithmic transformation of data on AIR$_g$, S$_i$, S$_g$,

and glucose disappearance rates because the untransformed data were not normally

distributed. Data in all the other Figures and Tables were inverse normally transformed and

multiplied by SD to have effect size in real units; all analyses in those Figures and Tables were

adjusted for age, sex, and BMI. Genetic association analysis (Table S3) was performed using

linear mixed models to account for familial correlation using the kinship relationship matrix as

implemented in the Mixed Model Analysis for Pedigree and population [https://mmap.github.io/].

Multiple regression analysis was conducted using Excel. Minimal model analyses were

conducted as described elsewhere [17-19]. Statistical significance was assessed using a paired t-

test. Although a p-value of p<0.05 was defined as the threshold for nominal statistical

significance, a more stringent threshold (e.g., p<0.001) may be appropriate to account for

multiple comparisons.

3 | Results

3.1 | Disposition and adverse events

Research participants' baseline characteristics are summarized in Table S1. Disposition of participants and adverse events are summarized in Fig. S1. Seventy-eight individuals were enrolled in this clinical trial between June, 2016 - November, 2018. Sixty-two participants completed frequently sampled intravenous glucose tolerance tests.

3.2 | Intravenous glucose tolerance tests: impact of exenatide

Intravenous administration of glucose triggered prompt increases in plasma levels of glucose and insulin (Fig. 1). Plasma glucose achieved a peak at ~4 min – after which time glucose levels decreased. Administration of exenatide augmented insulin secretion. We defined indices to quantitate exenatide's direct effect on glucose-simulated insulin secretion and exenatide's indirect effect on the rate of glucose disappearance (Table S2). As illustrated by the time course of insulin levels in exenatide-treated individuals (Fig. 1), insulin secretion was biphasic. Consistent with published literature [20,21], the area-under-the-curve (AUC) between 0-10 min provides an index of first phase insulin secretion (Table S2). We used AUC between 10-50 min as an index of second phase insulin secretion. The "cut-off" point at 10 min was selected because that was the time of the nadir separating the first peak of insulin levels from the second peak in exenatide-treated individuals (Fig. 1). The higher plasma insulin levels observed in exenatide-treated individuals accelerated the rate at which glucose levels declined. During the time interval between 25-50 min, the plot of log(glucose) versus time approximates a straight line. We used the slope of that line as an index of the rate at which glucose disappeared from the circulation (Table S2) [20]. Exenatide triggered statistically significant increases in the areas under the curve (AUCs) for first phase (~1.9-fold; $p=1.9 \times 10^{-9}$; Fig. S2) and second phase (~3.5-fold; $p=1 \times 10^{-9}$) insulin secretion as well as the rate at which plasma glucose levels decreased

(~2.4-fold; p=2×10^{-10}; Fig. S2). Values for first phase and second phase insulin secretion were

closely correlated (r=0.46, p=0.0005 for placebo data; r=0.57, p=5.4×10^{-6} for data after

administration of exenatide) (Fig. S3).

Because curves describing time courses for mean glucose levels in the placebo and exenatide

studies are essentially superimposable during the first ten minutes (Fig. 1), the drug effect on

first phase insulin secretion likely represents a direct effect of exenatide. In contrast, exenatide's

effect on second phase insulin secretion (10-50 min) likely reflects a balance between

exenatide's positive direct effect on insulin secretion and the negative impact of lower glucose

levels tending to decrease insulin secretion. Accordingly, we have emphasized first phase

insulin secretion to assess the correlation between insulin secretion and the rate of glucose

disappearance. The rate of glucose disappearance (as defined in Table 1) was correlated with

first phase insulin secretion (r=0.74, p=2.4×10^{-10} for placebo data; r=0.63, 3.4×10^{-7} for data

after administration of exenatide) (Fig. 2AB). As illustrated in the histograms (Fig. S4), we

observed substantial inter-individual variation in indices for drug effects on both stimulation of

insulin secretion and acceleration of glucose disappearance. While exenatide exerted little or no

effect in some individuals, greater than 5-fold increases were observed in other individuals.

3.2 | Intravenous glucose tolerance tests: exenatide increases glucose effectiveness

Exenatide's effect on the rate of glucose disappearance was correlated with the magnitude of

exenatide's effect on insulin secretion (r=0.70; p=9.2×10^{-9}) (Fig. 2C). The correlation coefficient

suggests that inter-individual variation in the magnitude of exenatide's direct effect on insulin

secretion explains approximately half of the observed variance in the magnitude of exenatide's

indirect effect on the rate of glucose disappearance. Accordingly, we searched for other factors

that might have contributed to variation in the effect of exenatide to accelerate glucose

disappearance. We applied Bergman's minimal model [10,16] to estimate insulin sensitivity (S_i),

glucose effectiveness (S_g), and disposition index (DI) (Table 1). Although acute administration of

exenatide appeared not to alter insulin sensitivity (p=0.36), exenatide treatment increased

glucose effectiveness by 32% (p=0.0008), acute insulin response to glucose by 94% ($p=2.3 \times 10^{-10}$)

and disposition index by 95% ($p=2.0 \times 10^{-6}$). The rate of glucose disappearance was

significantly correlated with glucose effectiveness for data from both placebo studies (r=0.50,

p=0.0001; Fig. 3) and exenatide studies ($r=0.66$, $p=5.4 \times 10^{-8}$; Fig. 3). We conducted multiple

regression analyses to further investigate inter-relationships among the parameters of the

minimal model in the context of acute administration of exenatide. In the placebo state, variation

in S_i and acute insulin response to glucose (AIR_g) both made similar magnitude contributions to

inter-individual variation in the rate of glucose disappearance. An increase of 1 standard

deviation unit (SDU) in each of these parameters was associated with an increase of ~0.4 SDU

in the rate of glucose disappearance (Table 2). Inter-individual variation in glucose effectiveness

made a smaller contribution (i.e., 0.2 SDU increase in glucose disappearance rates for each

SDU increase in S_g) (Table 2). After exenatide administration, variation in all three parameters

also contributed, but the effect of variation in AIR_g predominated (an increase of 0.61 SDU in the

rate of glucose disappearance per 1 SDU increase in insulin secretion); the impact of variations

in insulin sensitivity and glucose effectiveness were smaller (Table 2). Variation in the

magnitude of the drug effect on insulin secretion was the principal determinant of the magnitude

of the drug effect on the rate of glucose disappearance. In addition, an increase of 1 SDU in the

drug effect on AIR_g was associated with an increase of 0.58 ± 0.12 SDU in the magnitude of the

drug effect for the rate of glucose disappearance ($p=7.2 \times 10^{-7}$) (Table 2).

3.3 | Effect of genotype

This pilot study was designed to test the hypothesis that missense variants in two candidate

genes (*GCGR* and *GIPR*) might be associated with pharmacodynamic responses to GLP1

receptor agonists. Table S3 compares pharmacodynamic responses to exenatide among three

groups of people: (a) individuals who are homozygous for the major alleles of both genes; (b)

homozygotes for the G40S variant of *GCGR* (rs1801483) [22,23]; and (c) homozygotes for the

E354Q variant of *GIPR* (rs1800437) [24-26] (Table S3). Four co-primary endpoints were pre-

specified: association of genotype (either G40S-*GCGR* or E354Q-*GIPR*) with the magnitude of

drug effect (i.e., either exenatide-induced augmentation of first phase insulin secretion or

exenatide-induced acceleration of the rate of glucose disappearance). We did not observe

statistically significant associations between any of the genetic variants and either of the

endpoints.

4 | Discussion

Pharmacogenomic research has utilized varied approaches – including acute studies in healthy volunteers assessing acute pharmacodynamic endpoints [3,27] and chronic studies in disease patients assessing routine clinical endpoints such as HbA1c [28]. Short-term studies in healthy volunteers offer several methodological advantages – for example, minimization of confounding factors caused by co-existing diseases and effects of changing co-medications during the course of the study. This pilot study provided an opportunity to validate pharmacodynamic endpoints for our currently ongoing genome-wide association study of the genetics of pharmacodynamic responses to a GLP1 receptor agonist (NCT05071898). As exemplified by the usual stepwise approach to drug development, it can be useful to conduct pilot studies to validate methods and analytic approaches before initiating a larger clinical trial. Our results confirm the existence of substantial inter-individual variation in pharmacodynamic responses to exenatide – ranging from no significant increase to a 5- to 6-fold increase for glucose-sensitive insulin secretion or acceleration of glucose disappearance, respectively. The wide range of inter-individual variation in the magnitude of drug response emphasizes the potential value of identifying genetic variants to predict an individual's pharmacological response and provide guidance to physicians in selecting the best diabetes drug for each individual patient.

FDA-approved prescribing information for GLP1R agonists identifies several important clinical benefits for this class of drugs – including, HbA1c-lowering in patients with type 2 diabetes, weight loss in overweight/obese patients, and decreasing major adverse cardiovascular events in patients with type 2 diabetes [29-31]. Our clinical trial assessed drug-induced acceleration of glucose disappearance in healthy non-diabetic individuals, which is mechanistically related to drug-induced HbA1c lowering in patients with type 2 diabetes. Mediation analysis of the LEADER cardiovascular outcome trial suggested that ~90% of liraglutide's beneficial impact on cardiovascular risk reduction was mediated by the drug-induced decrease in HbA1c [32]. This

suggests that genetic variants associated with glycemic effects may also contribute to predicting

the magnitude of cardiovascular risk reduction. A similar conclusion was reached in a

comparative effectiveness analysis comparing different GLP1R agonists. The drugs providing

the largest HbA1c-lowering also provided the greatest cardioprotection [33,34].

4.1 | Acute exenatide-induced acceleration of glucose disappearance: mechanisms

Exenatide increased the magnitude of the glucose-induced increase in insulin secretion by 1.9-

fold for 1st phase insulin secretion, by 3.5-fold increase for 2nd phase insulin secretion, and by

2.1-fold increase for the rate of glucose disappearance (Figs. 1 and S2; Table 1). Furthermore,

exenatide caused a 32% increase in mean glucose effectiveness (S_g) but did not induce a

significant change in insulin sensitivity (Table 1). The impact of the exenatide-induced increase

in S_g is supported by the observation that rates of glucose disappearance were correlated with

the magnitude of S_g in both placebo studies and studies conducted after participants received

exenatide (Fig. 3). Multiple regression analysis revealed that inter-individual variation in the

magnitudes of glucose-stimulated insulin secretion and insulin sensitivity appeared to contribute

significantly to inter-individual variation in the rate of glucose disappearance in both placebo

studies and studies conducted after participants received exenatide (Table 2). Thus, although

exenatide does not exert an acute effect on insulin sensitivity, pre-existing inter-individual

variation in S_i does contribute significantly to inter-individual variation in rates of glucose

disappearance both at baseline and in the exenatide-treated states (Table 2). Notwithstanding

smaller contributions from S_g and S_i, inter-individual variation in the magnitude of exenatide-

induced increase in glucose-sensitive insulin secretion (AIR$_g$) was quantitatively the most

important determinant of the magnitude of the drug-induced increase in glucose disappearance

(Table 2); a change of 1 SDU in the drug effect on AIR$_g$ was associated with a 0.58 SDU in the

drug effect on the rate of glucose disappearance. These data on effects of exenatide on sub-

phenotypes (i.e., insulin secretion and glucose disappearance rate) are generally similar to what

has been reported for liraglutide and lixisenatide [20,21] with the exception that lixisenatide was

reported not to induce a statistically significant increase in 2nd phase insulin secretion in healthy

individuals [21].

The term "glucose effectiveness" refers to insulin-independent mechanisms whereby glucose

concentrations enhance glucose utilization [8]. The precise physiological mechanisms mediating

glucose effectiveness are not completely understood [8]. There has been discussion about

challenges in estimating glucose effectiveness from data derived from intravenous glucose

tolerance tests. For example, it has been suggested that higher levels of insulin secretion may

lead to higher mathematical estimates of glucose effectiveness; it has been challenging to

identify detailed mechanisms accounting for these higher estimates of S_g [15,34]. In any case, it is

theoretically possible that the exenatide-induced increase in insulin secretion may contribute to

the larger mathematical estimates of S_g. Bergman [8] has suggested that glucose effectiveness

may reflect hepatic glucose uptake and metabolism (mediated by GLUT2 and glucokinase). As

GLP1 receptor agonists have been reported to suppress glucagon levels [11], this might provide

an endocrine mechanism whereby exenatide might exert an indirect effect on hepatic glucose

metabolism. However, to the extent that effects of exenatide on glucagon secretion by α-cells

might be mediated at least in part by paracrine β-cell insulin secretion, such an effect would not

necessarily be classified as being insulin-independent. In any case, further research will be

required to elucidate physiological mechanisms mediating acute effects of GLP1 receptor

agonists on glucose effectiveness.

4.2 | Pharmacogenomic candidate genes

A missense variant in the *GLP1R* gene (rs6923761; p.T149M) has previously been reported to

be associated with a diminished response to GLP1 receptor agonists [6,7,35] . We have not

detected this variant in DNA sequences in the Old Order Amish. Recent literature has

suggested the existence of positive crosstalk among GLP1, GIP, and glucagon with respect to

their beneficial effects on insulin secretion and weight loss [36] . These considerations led to the

design of tirzepatide – a recently approved "twincretin" combining agonist activity against both

GLP1R and GIPR [37]. Based on these data, we hypothesized that there might be

pharmacologically relevant interactions between an exogenous GLP1R agonist and

endogenous glucagon or GIP. To test these hypotheses, we recruited individuals who are

homozygous for two relatively common missense variants: rs1801483 (p.G40S) in *GCGR* and

rs1800437 (p.E354Q) in *GIPR*. The p.E354Q variant in *GIPR* has been reported to enhance

agonist-induced receptor desensitization – potentially leading to resistance to the effect of GIP

agonists. Furthermore, this genetic variant in *GIPR* has been reported to be associated with

increased plasma levels of GIP as well as various anthropometric and glycemic traits [38]. The

p.G40S variant in *GCGR* has been reported to impair signaling through β-arrestin-1 [23]. This

p.G40S variant in *GCGR* has been reported to be associated with diabetes [22], but this finding

seems not to be reproducible [39].

Although we observed numerical decreases of 20-25% in the magnitude of the effect of

exenatide-induced effect on first phase glucose-stimulated insulin secretion in homozygotes for

variants in both *GIPR* (rs1800437) and *GCGR* (rs1801483), these numerical differences were

not statistically significant. We encountered greater than expected difficulty in recruiting

research participants with the genotypes of interest. The small size of the study population

creates uncertainty about the interpretation of our observations – i.e., whether the statistically

insignificant numerical trends toward a decrease in the response to exenatide might possibly

represent type II error (incorrect rejection of a false null hypothesis). Further research will be

required to resolve these uncertainties. Whether or not the missense variant in *GIPR* alters the

response to a selective GLP1R agonist, it would be of interest to determine whether the variant in

GIPR is associated with variation in response to peptides possessing GIPR agonist activity

(including tirzepatide) [37].

ACKNOWLEDGEMENTS

We gratefully acknowledge funding provided by the American Diabetes Association (grant

number 1-16-ICTS-112) and National Institute of Diabetes and Digestive and Kidney Disease

(R01DK130238, T32DK098107, and P30DK072488). We also gratefully acknowledge

contributions of the research participants and the skilled staff at the Amish Research Clinic for

their critical roles in making this study possible. We are grateful to Mary Pavlovich, Melanie

Daue, and Kathy Ryan for their help with database management. Dr. Laura Yerges-Armstrong

provided genotype data enabling us to identify individuals to be invited to participate in this

genotype-guided recruitment study.

<u>AUTHORS' CONTRIBUTIONS</u>

Conception of the clinical trial and PI for the grant from the American Diabetes Association grant

*(*1-16-ICTS-112*)*: SIT

<u>Acquisition and analysis of data</u>: ALB, AHY, MEM, EAS, SIT, HBW, ZSY

<u>Minimal model analysis of FSIGT data</u>: RM, HF

<u>Establishment of Old Order Amish genotype database</u>: BDM, ARS

<u>Preparation of first draft of manuscript</u>: SIT

<u>Revising and approving final version of manuscript</u>: all authors

<u>Overall accountability for all aspects of work</u>: SIT

Competing Interests

SIT serves as a consultant for Ionis Pharmaceuticals and receives an inventor's share of

royalties from NIDDK for metreleptin as a treatment for generalized lipodystrophy. ARS is an

employee of Regeneron Genetics Center. BDM and MEM receive grant support from

Regeneron Genetics Center. BDM, MEM, EAS, and HBW have received partial salary support

from funds provided by RGC. ALB, ZSY, RM, and HF declare no competing interests.

Table 1. Parameters from minimal model analyses. This Table summarizes data from 45

frequently sampled intravenous glucose tolerance tests conducted after research participants

received either saline (placebo) or exenatide. Data are presented as means ± SEM. The first

five rows present analyses of untransformed data whereas the next five rows present analyses

of logarithmically transformed data. Paired t-tests were conducted on the logarithmically

transformed data; two-sided p-values are presented in the last column of the Table. Rates of

glucose disappearance were calculated as described in Table S2.

Parameter	Placebo	Exenatide	p-value
Insulin sensitivity (S_i) [a]	6.80 ± 0.60	7.07 ± 0.58	
Glucose effectiveness (S_g) [b]	0.0139 ± 0.0010	0.0183 ± 0.010	
Acute insulin response (AIR_g) [c]	243 ± 24	472 ± 56	
Disposition index (DI)	1454 ± 157	2833 ± 288	
Glucose disappearance rate	506 ± 31	1060 ± 70	
Log (S_i)	0.73 ± 0.05	0.78 ± 0.04	0.36
Log (S_g)	-1.92 ± 0.04	-1.76 ± 0.03	0.0008
Log (AIR_g)	2.31 ± 0.04	2.58 ± 0.04	2.3×10^{-10}
Log (DI)	3.04 ± 0.05	3.36 ± 0.04	2.0×10^{-6}
Log (glucose disappearance rate)	2.66 ± 0.03	2.96 ± 0.04	1.4×10^{-13}

[a] units: $10^{-4} \cdot min^{-1} / [\mu U/mL]$

[b] units: min^{-1}

[c] units: $\mu U \cdot mL^{-1} \cdot min^{-1}$

Table 2. Relative contributions to the rate of glucose disappearance: beta coefficients
from multiple regression of parameters derived from minimal model analysis. The Table
presents results of multiple regression analyses with three independent variables derived from
minimal model analysis of frequently sampled intravenous glucose tolerance tests. The first two
columns present data on logarithmically transformed values of insulin sensitivity (S_i), glucose
effectiveness (S_g), and acute insulin response to glucose (AIR_g) in studies where participants
received either saline (placebo) or exenatide. The last column presents analysis of
logarithmically transformed data on effects of exenatide (i.e., "drug effects" calculated as
specified in Table S2) on insulin sensitivity (S_i), glucose effectiveness (S_g), and acute insulin
response to glucose (AIR_g). in each analysis, the dependent variable was the rate of glucose
disappearance as defined in Table S2. Beta values are expressed in standard deviation units
(SDU) – i.e., the change in the dependent variable relative to the change in the independent
variable in SDU. The last row of the Table presents the overall two-sided p-value for each
multiple regression model as calculated using Excel. The footnotes indicate two-sided p-values
for each of the coefficients. Units for the minimal model parameters are summarized in Table 1.

388
389

Parameter	Placebo	Exenatide	Drug Effect
Insulin sensitivity (S_i)	0.39 ± 0.16[d]	0.37 ± 0.09[c]	0.14 ± 0.11[e]
Glucose effectiveness (S_g)	0.20 ± 0.16[gd]	0.21 ± 0.09[f]	0.27 ± 0.13[g]
Acute insulin response (AIR_g)	0.41 ± 0.15[c]	0.61 ± 0.13[b]	0.58 ± 0.12[a]
p-value	0.009	1.9x10⁻⁶	5.3x10⁻⁸

390
391 [a] p=7.2 x 10⁻⁷; [b] p=0.0004; [c] p=0.01 [d] p=0.02; [e] p=0.03; [f] p=0.15; [g] p=0.23
392
393

Figure 1. Exenatide enhances insulin secretion and accelerates the rate of glucose

disappearance decrease in frequently sampled intravenous glucose tolerance tests

(FSIGT).

Fifty-three non-diabetic healthy volunteers participated in a randomized crossover study of

exenatide (N=53). After an overnight fast, participants were randomly assigned to receive either

exenatide (5 µg, s.c.; solid circles) or saline (0.2 mL, s.c.; open circles). The FSIGT was initiated

15 min after the s.c. injection by administration of glucose (0.3 g/kg, i.v.) over two minutes.

Blood samples were obtained for measurement of plasma glucose (panel A) and plasma insulin

(panel B) over the course of 180 min after glucose administration as described in the Methods

section [8,16-18]. After a washout period of 5-28 days, a second FSIGT was conducted in which the

participant received the treatment (either saline or exenatide) not administered for the first

FSIGT.

407
408

409
410

Figure 2. Correlations between the rate of glucose disappearance and first phase insulin

secretion. Glucose-stimulated insulin secretion accelerates the rate of glucose disappearance,

which in turn provides an "off" signal for insulin secretion. This analysis demonstrates that the

index for the rate of glucose disappearance between 25-50 min (Table 1) is correlated with the

index for first phase insulin secretion (Table 1) in both the placebo-FSIGT (panel A; r=0.74;

p=2.4x10^{-10}) and the exenatide-FSIGT (panel B; r=0.63; p=3.4x10^{-7}). Indices for effects of

exenatide on first phase insulin secretion and the rate of glucose disappearance are defined in

Table 1. The index for exenatide-induced acceleration of glucose disappearance is correlated

with the index for exenatide-induced insulin secretion (panel C; r=0.70; p=9.2x10^{-9}). Areas under

the curve for 1st phase insulin secretion are expressed in the following units: (µU/mL) · min.

Figure 3. Correlation of rate of glucose disappearance with glucose effectiveness (S_g).

Rates of glucose disappearance (vertical axis) are plotted as a function of glucose effectiveness

(S_g) (horizontal axis). The correlation coefficients and p-values are indicated in the Figures for

the placebo studies (left panel) and the exenatide studies (right panel). Values of Sg are

expressed in the following units: min^{-1}. Rates of glucose disappearance were calculated as

summarized in Table S2.

REFERENCES

1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care.* 2012;35(6):1364-1379.

2. Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. *Diabetes Care.* 2018;41(2):258-266.

3. Pawlyk AC, Giacomini KM, McKeon C, Shuldiner AR, Florez JC. Metformin pharmacogenomics: current status and future directions. *Diabetes.* 2014;63(8):2590-2599.

4. Pearson ER. Dorothy Hodgkin Lecture 2021: Drugs, genes and diabetes. *Diabet Med.* 2021;38(12):e14726.

5. Rathmann W, Bongaerts B. Pharmacogenetics of novel glucose-lowering drugs. *Diabetologia.* 2021;64(6):1201-1212.

6. Chedid V, Vijayvargiya P, Carlson P, et al. Allelic variant in the glucagon-like peptide 1 receptor gene associated with greater effect of liraglutide and exenatide on gastric emptying: A pilot pharmacogenetics study. *Neurogastroenterol Motil.* 2018;30(7):e13313.

7. Mashayekhi M, Wilson JR, Jafarian-Kerman S, et al. Association of a glucagon-like peptide-1 receptor gene variant with glucose response to a mixed meal. *Diabetes Obes Metab.* 2021;23(1):281-286.

8. Bergman RN. Origins and History of the Minimal Model of Glucose Regulation. *Front Endocrinol (Lausanne).* 2020;11:583016.

9. Drucker DJ. The Ascending GLP-1 Road From Clinical Safety to Reduction of Cardiovascular Complications. *Diabetes.* 2018;67(9):1710-1719.

10. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. *Cell Metab.* 2018;27(4):740-756.

11. McLean BA, Wong CK, Campbell JE, Hodson DJ, Trapp S, Drucker DJ. Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation. *Endocr Rev.* 2021;42(2):101-132.

12. Gutniak M, Orskov C, Holst JJ, Ahren B, Efendic S. Antidiabetogenic effect of glucagon-like
peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. *N Engl J Med.*
1992;326(20):1316-1322.

13. D'Alessio DA, Kahn SE, Leusner CR, Ensinck JW. Glucagon-like peptide 1 enhances
glucose tolerance both by stimulation of insulin release and by increasing insulin-
independent glucose disposal. *J Clin Invest.* 1994;93(5):2263-2266.

14. Shalev A, Ninnis R, Keller U. Effects of glucagon-like peptide 1 (7-36 amide) on glucose
kinetics during somatostatin-induced suppression of insulin secretion in healthy men. *Horm*
Res. 1998;49(5):221-225.

15. Meneilly GS, McIntosh CH, Pederson RA, et al. Effect of glucagon-like peptide 1 on non-
insulin-mediated glucose uptake in the elderly patient with diabetes. *Diabetes Care.*
2001;24(11):1951-1956.

16. Beard JC, Bergman RN, Ward WK, Porte D, Jr. The insulin sensitivity index in nondiabetic
man. Correlation between clamp-derived and IVGTT-derived values. *Diabetes.*
1986;35(3):362-369.

17. Quon MJ, Cochran C, Taylor SI, Eastman RC. Non-insulin-mediated glucose disappearance
in subjects with IDDM. Discordance between experimental results and minimal model
analysis. *Diabetes.* 1994;43(7):890-896.

18. Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity
and resistance in vivo: advantages, limitations, and appropriate usage. *Am J Physiol*
Endocrinol Metab. 2008;294(1):E15-26.

19. Fosam A, Yuditskaya S, Sarcone C, Grewal S, Fan H, Muniyappa R. Minimal Model-Derived
Insulin Sensitivity Index Underestimates Insulin Sensitivity in Black Americans. *Diabetes*
Care. 2021;44(11):2586-2588.

20. Elbrond B, Jakobsen G, Larsen S, et al. Pharmacokinetics, pharmacodynamics, safety, and
tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in
healthy male subjects. *Diabetes Care.* 2002;25(8):1398-1404.

21. Becker RH, Stechl J, Msihid J, Kapitza C. Lixisenatide resensitizes the insulin-secretory
response to intravenous glucose challenge in people with type 2 diabetes--a study in both
people with type 2 diabetes and healthy subjects. *Diabetes Obes Metab.* 2014;16(9):793-
800.

22. Hager J, Hansen L, Vaisse C, et al. A missense mutation in the glucagon receptor gene is
associated with non-insulin-dependent diabetes mellitus. *Nat Genet.* 1995;9(3):299-304.

23. van der Velden WJC, Lindquist P, Madsen JS, et al. Molecular and in vivo phenotyping of
missense variants of the human glucagon receptor. *J Biol Chem.* 2022;298(2):101413.

24. Fortin JP, Schroeder JC, Zhu Y, Beinborn M, Kopin AS. Pharmacological characterization of
human incretin receptor missense variants. *J Pharmacol Exp Ther.* 2010;332(1):274-280.

25. Gabe MBN, van der Velden WJC, Gadgaard S, et al. Enhanced agonist residence time,
internalization rate and signalling of the GIP receptor variant [E354Q] facilitate receptor
desensitization and long-term impairment of the GIP system. *Basic Clin Pharmacol Toxicol.*
2020;126 Suppl 6:122-132.

26. Mohammad S, Patel RT, Bruno J, Panhwar MS, Wen J, McGraw TE. A naturally occurring
GIP receptor variant undergoes enhanced agonist-induced desensitization, which impairs
GIP control of adipose insulin sensitivity. *Mol Cell Biol.* 2014;34(19):3618-3629.

27. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19
genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. *JAMA.*
2009;302(8):849-857.

28. Zhou K, Yee SW, Seiser EL, et al. Variation in the glucose transporter gene SLC2A2 is
associated with glycemic response to metformin. *Nat Genet.* 2016;48(9):1055-1059.

29. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in
type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. *Lancet.*
2019;394(10193):121-130.

30. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients
with Type 2 Diabetes. *N Engl J Med.* 2016;375(19):1834-1844.

31. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes
in Type 2 Diabetes. *N Engl J Med.* 2016;375(4):311-322.

32. Buse JB, Bain SC, Mann JFE, et al. Cardiovascular Risk Reduction With Liraglutide: An
Exploratory Mediation Analysis of the LEADER Trial. *Diabetes Care.* 2020;43(7):1546-1552.

33. Taylor SI. GLP-1 receptor agonists: differentiation within the class. *Lancet Diabetes*
Endocrinol. 2018;6(2):83-85.

34. Aroda VR, Eckel RH. Reconsidering the role of glycaemic control in cardiovascular disease
risk in type 2 diabetes: A 21st century assessment. *Diabetes Obes Metab.*
2022;24(12):2297-2308.

35. Maselli D, Atieh J, Clark MM, et al. Effects of liraglutide on gastrointestinal functions and
weight in obesity: A randomized clinical and pharmacogenomic trial. *Obesity (Silver Spring).*
2022;30(8):1608-1620.

36. Capozzi ME, DiMarchi RD, Tschop MH, Finan B, Campbell JE. Targeting the
Incretin/Glucagon System With Triagonists to Treat Diabetes. *Endocr Rev.* 2018;39(5):719-
738.

37. Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in
Patients with Type 2 Diabetes. *N Engl J Med.* 2021;385(6):503-515.

38. Bowker N, Hansford R, Burgess S, et al. Genetically Predicted Glucose-Dependent
Insulinotropic Polypeptide (GIP) Levels and Cardiovascular Disease Risk Are Driven by
Distinct Causal Variants in the GIPR Region. *Diabetes.* 2021;70(11):2706-2719.

39. Huang X, Orho M, Lehto M, Groop L. Lack of association between the Gly40Ser
polymorphism in the glucagon receptor gene and NIDDM in Finland. *Diabetologia.*
1995;38(10):1246-1248.

Acute pharmacodynamic responses to exenatide:

Drug-induced increases in insulin secretion and glucose effectiveness

Simeon I. Taylor MD, PhD[1] | May E. Montasser PhD[1] | Ashley H. Yuen MD[1] |

Hubert Fan[2] | Zhinoosossadat Shahidzadeh Yazdi MD[1] | Hilary B. Whitlatch MD[1] |

Braxton D. Mitchell PhD, MPH[1] | Alan R. Shuldiner MD[1] | Ranganath Muniyappa MD PhD[2] |

Elizabeth A. Streeten MD[1] | Amber L. Beitelshees PharmD, MPH[1]

[1] Department of Medicine, Division of Endocrinology, Diabetes, and Nutrition, University of

Maryland School of Medicine, Baltimore, MD 21201, USA

[2] Diabetes, Endocrinology, and Obesity Branch, National institute of Diabetes and Digestive and

Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA

Correspondence

Simeon I. Taylor, MD, PhD, Department of Medicine, University of Maryland School of Medicine,

Baltimore, MD 21201, USA

Email: staylor2@som.umaryland.edu

Funding information

American Diabetes Association (1-16-ICTS-112) and National Institute of Diabetes and

Digestive and Kidney Disease (R01DK130238, T32DK098107, and P30DK072488)

<u>Table of Contents</u>

1 | Exclusion Criteria

- Known allergy to exenatide

- History of diabetes, random glucose >200 mg/dL, or HbA1c $\geq$ 6.5%

- Significant cardiac, hepatic, pulmonary, or renal disease or other diseases that the investigator judged would make interpretation of the results difficult or increase the risk of participation

- Seizure disorder

- Pregnant by self-report or known pregnancy within 3 months of the start of study

- Currently breast feeding or breast feeding within 3 months of the start of the study

- Estimated glomerular filtration rate <60 mL/min/1.73m^2

- Hematocrit <35%

- Liver function tests greater than 2 times the upper limit of normal

- Abnormal TSH

- History of pancreatitis or pancreatic cancer. Personal or family history of medullary carcinoma of the thyroid.

2 | Clinical Chemistry

Screening blood samples were obtained by a research nurse during home visits and collected in test tubes as appropriate for each assay: EDTA anticoagulant (purple top tube) for measurement of hematocrit and HbA1c; heparin anticoagulant (green top tube) for measurement of TSH; gray top tubes containing sodium fluoride and potassium oxalate for measurement of fasting plasma glucose; red top tube for collecting serum samples. After placing gray, purple, and green top tubes on ice, blood samples were transported to the clinical laboratory at the Amish Research Clinic (maximum transport time, 2 hours). After centrifugation (3300 rpm for 10 min), plasma/serum was sent on the same day to Quest Diagnostics for assay. Blood samples for the frequently sampled intravenous glucose tolerance test were collected in EDTA-containing purple top tubes for measurement of plasma insulin and in EDTA/oxalate-containing gray top tubes for measurement of plasma glucose. Glucose was measured in duplicate using an YSI glucose analyzer. Insulin was assayed in duplicate following the manufacturer's directions using reagents in kits (#10-1113-01) purchased from Mercodia Inc.

69 **Table S1. Demographics and baseline characteristics of study population**

Mean ± SEM (range)	Males	Females	Total
N (sample size)	33	21	54
Age (years)	46.0 ± 2.0	52.0 ± 2.1	48.3 ± 1.5
BMI (kg/m^2)	27.3 ± 0.6	28.9 ± 0.8	27.9 ± 0.5
HbA1c (%)	5.51 ± 0.6	5.60 ± 0.7	5.54 ± 0.4
Serum creatinine (mg/dL)	0.88 ± 0.02	0.73 ± 0.02	0.82 ± 0.02
eGFR (mL/min/1.73 m^2)	101.2 ± 2.2	94.5 ± 3.4	98.6 ± 1.9
Hematocrit (%)	43.6 ± 0.4	39.0 ± 0.5	41.8 ± 0.4
Aspartate amino transferase (U/L)	18.5 ± 0.8	17.4 ± 0.9	18.1 ± 0.6
Alanine amino transferase (U/L)	21.0 ± 1.4	17.3 ± 1.1	19.6 ± 1.0

71 **Table S2. Definition of parameters for statistical analyses**

Parameter	Definition
1st phase insulin secretion	Area under the curve (AUC) for plasma insulin levels (0-10 min) calculated by trapezoidal rule
2nd phase insulin secretion	Area under the curve for plasma insulin levels (10-50 min) calculated by trapezoidal rule
Glucose disappearance rate	Slope of the plot of the logarithm of glucose concentration versus time (25-50 min) calculated as the slope of the least square fit using Excel.
Drug effect: 1st phase insulin secretion	Logarithm of AUC for 1st phase insulin secretion when participant received exenatide – logarithm of AUC for 1st phase insulin secretion when participant received saline.
Drug effect: 2nd phase insulin secretion	Logarithm of AUC for 2nd phase insulin secretion when participant received exenatide *minus* logarithm of AUC for 2nd phase insulin secretion when participant received saline.
Drug effect: glucose disappearance rate	Glucose disappearance rate when participant received exenatide *minus* the glucose disappearance rate when participant received saline.
Log-transformed glucose disappearance rate	Logarithm of slope of the plot of the logarithm of glucose concentration versus time (25-50 min) calculated as the slope of the least square fit using Excel.
Drug effect: log-transformed glucose disappearance rate	Logarithm of glucose disappearance rate when participant received exenatide *minus* logarithm of the glucose disappearance rate when participant received saline.

73   **Table S3. Interactions of genotype with pharmacodynamic responses to exenatide.**

Treatment	Trait	WT	GCGR Homozygotes (rs1801483)	GIPR Homozygotes (rs1800437)
Placebo	Insulin AUC – 1st phase	270 ± 35	248 ± 23	322 ± 55
Placebo	Insulin AUC – 2nd phase	828 ± 125	753 ± 77	736 ± 99
Placebo	Glucose disappearance	3.87 ± 0.24	4.23 ± 0.34	4.58 ± 0.38
Exenatide	Insulin AUC – 1st phase	586 ± 75	409 ± 41	606 ± 144
Exenatide	Insulin AUC – 2nd phase	3171 ± 51	2205 ± 107	2399 ± 440
Exenatide	Glucose disappearance	10.08 ± 0.69	10.68 ± 0.61	10.19 ± 1.03
Drug Effect	Insulin AUC – 1st phase	2.41 ± 0.25	1.80 ± 0.19	1.90 ± 0.25
Drug Effect	Insulin AUC – 2nd phase	4.07 ± 0.46	3.22 ± 0.27	3.31 ± 0.44
Drug Effect	Glucose disappearance	2.94 ± 0.35	2.78 ± 0.35	2.24 ± 0.17

Figure S1. CONSORT diagram summarizing disposition of research participants. Seventy-

eight individuals were enrolled in this clinical trial between June, 2016 – November, 2018. Sixty-

two participants completed frequenty sampled glucose tolerance tests. Twelve enrollees were

excluded for the following reasons (Fig. S1): low hematocrit (N=1), abnormal TSH levels (N=5),

abnormal liver function tests (N=1), family history of medullary carcinoma of the thyroid (N=1),

primary hyperparathyroidism (N=1), low eGFR (N=1), poor venous access (N=1), and treatment

with warfarin (N=1). Thus, 66 individuals were judged to be eligible for the clinical trial. Three

individuals changed their minds and withdrew from the study after providing informed consent

but before undergoing an intravenous glucose tolerance test; technical challenges during one

FSIGT led to withdrawal of an additional participant. The remaining 63 participants completed

the study. Ten individuals were excluded from the data base either because of missing data

(N=9) or outlier data (N=1). Thus, data from 53 individuals comprised the final database for

most of the analyses. Data from eight individuals' placebo FSIGTs could not be analyzed with

the Minimal Model softwared because of issues related to data quality. Accordingly, Minimal

Model analysis of the FSIGT was based on data from 45 individuals. There were 27 reported

adverse events of mild to moderate severity. Two participants reported feeling light-headed or

dizzy in the evening after leaving the Amish Research Clinic; these were classified as probably

being related to the study. There were 11 events in which a participant's plasma glucose

(determined using a glucometer) was <70 mg/dL (52-63 mg/dL) at the end of an FSIGT. Three

participants reported symptoms (weakness, lightheadedness, or not feeling well) 60-90 minutes

after receiving intravenous glucose, at which time glucometer readings of 42 – 60 mg/dL were

obtained. Symptoms resolved quickly in all cases without intervention, and the FSIGT was not

terminated. These were judged to be mild in severity and probably caused by the study.

Enrolled in clinical trial
(06/2016 – 11/2018)
78 Healthy Volunteers

Exclusions (12)

Abnormal lab tests
Abnormal thyroid tests (5)
Anemia (1)
Hyperparathyroidism (1)
eGFR <60 mL/min/1.73 m^2 (1)
Abnormal liver function tests (1)

Medical history:
Taking warfarin (1)
Poor venous access (1)
Medullary ca. thyroid (family history) (1)

Completed clinical trial
62 Healthy Volunteers

Non-completers
Withdrew consent (3)
Technical difficulty in FSIGT (1)

Missing Data
Missing samples in FSIGT (8)
Minimal model (quality control) (8)
Outlier data (1)

Database for Analysis
53 for FSIGT data
45 for minimal model data

Adverse Events
Headache (9)
Nausea/vomiting (5)
Diarrhea (2)
Glucometer reading <70 mg/dL (11)

101
102

Figure S2. Exenatide increases first phase insulin secretion and the rate of glucose

disappearance in frequently sampled intravenous glucose tolerance tests. Data are

presented as means of data for 53 research participants. The boxes encompass the 2nd and 3rd

quartiles; the "whiskers" correspond to the top and bottom quartiles (excluding outliers).

"Outliers" are depicted by the closed circles. Statistical significance (calculated using a paired t-

test) is indicated on the graphs. Areas under the curve for 1st and 2nd phase insulin secretion are

expressed in the following units: (µU/mL) · min.

Figure S3. Correlations between first and second phase insulin secretion. Intravenous

glucose triggers a biphasic response in the FSIGT: first phase insulin secretion (0-10 min) and

second phase insulin secretion (10-50 min). Data are plotted as the logarithms of the areas

under the curves for first and second phase insulin secretion; placebo studies are plotted in the

left panel and exenatide studies in the right panel. Values for correlation coefficients (r) and p-

values are indicated in the figure. Areas under the curve for 1st and 2nd phase insulin secretion

are expressed in the following units: (µU/mL) · min.

Figure S4. Inter-individual variation in magnitude of responses to exenatide: first phase

insulin secretion and rate of glucose disappearance. Indices for effects of exenatide on first

phase insulin secretion and the rate of glucose disappearance are defined in Table 1.

Histograms depicting inter-individual variation are presented in the left panel for first phase

insulin secretion and the right panel for the rate of glucose disappearance.